Rapid Escalation of Lipid Lowering Therapy to Reduce Recurrent Cardiovascular Event (REDUCE) All Comers Study

What this Trial Is About

This research aims to evaluate the impact of frequent monitoring and adjustment of lipid-lowering therapy (LLT) to achieve target low-density lipoprotein cholesterol (LDL-C) levels in patients with hyperlipidemia and cardiovascular disease. The study focuses on patients with acute or chronic coronary syndrome due to atherosclerotic coronary artery disease. Despite guidelines recommending aggressive LDL-C lowering primarily with statins, many patients do not reach their LDL-C goals due to factors like non-adherence and limited use of additional therapies. Participants include patients diagnosed with acute or chronic coronary syndrome caused by atherosclerosis. The study observes how frequent LDL-C testing and timely changes in LLT at a specialist clinic affect LDL-C control. There is no interventional treatment assigned; rather, the study collects data on LDL-C levels and therapy adjustments over time to assess current clinical practice strategies. During the study, LDL-C levels will be measured at baseline and at weeks 8, 26, and 52. Researchers will also monitor participants' achievement of LDL-C targets, adherence to lipid-lowering therapy, tolerability, and any major cardiovascular events. Quality of life will be assessed using the 12-Item Short Form Survey at the same time points. The study is observational, with follow-up lasting up to one year to gather comprehensive data on lipid management and cardiovascular outcomes.

Rapid Escalation of LipiD Lowering Therapy to Reduce RecUrrent Cardiovascular Event